Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to 11.77%.

  • 10x Genomics' EBITDA Margin rose 184300.0% to 11.77% in Q4 2025 from the same period last year, while for Dec 2025 it was 9.49%, marking a year-over-year increase of 223700.0%. This contributed to the annual value of 9.49% for FY2025, which is 223700.0% up from last year.
  • Latest data reveals that 10x Genomics reported EBITDA Margin of 11.77% as of Q4 2025, which was up 184300.0% from 21.64% recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' EBITDA Margin ranged from a high of 17.42% in Q2 2025 and a low of 61.7% during Q3 2023
  • Over the past 5 years, 10x Genomics' median EBITDA Margin value was 27.31% (recorded in 2024), while the average stood at 26.36%.
  • Per our database at Business Quant, 10x Genomics' EBITDA Margin skyrocketed by 3573500bps in 2021 and then plummeted by -455400bps in 2022.
  • 10x Genomics' EBITDA Margin (Quarter) stood at 12.97% in 2021, then dropped by -14bps to 14.78% in 2022, then tumbled by -103bps to 30.0% in 2023, then fell by -1bps to 30.2% in 2024, then skyrocketed by 61bps to 11.77% in 2025.
  • Its last three reported values are 11.77% in Q4 2025, 21.64% for Q3 2025, and 17.42% during Q2 2025.